Company intelligence / Profile preview

LYZZ Alpha Holding Ltd

Ownership: Private
Employees: ~17
Development stage: Phase 3

Overview

LYZZ Alpha Holding Ltd sponsored a completed Phase I/II, open-label, multi-center study evaluating AZD3759 for safety, tolerability, pharmacokinetics, and anti-tumor activity in Chinese patients with EGFR mutation-positive NSCLC with CNS metastases. The trial included dose escalation and expansion phases. Clinical results are not detailed publicly but the trial was completed as per registry information.

Therapeutic areas: Oncology
Modalities: Small molecules (notably tyrosine kinase inhibitors)
Industry: Biotech

Drug pipeline

1 asset

zorifertinib

Phase 3

Indications: Non-small cell lung cancer, Brain metastases

Partnerships

Lyzz Healthcare Venture Fund incubated the company’s lead asset and supported its development.

Beyond the preview

Go deeper on LYZZ Alpha Holding Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYZZ Alpha Holding Ltd.

Explore the full profile